Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA (YISTAR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03589833 |
Recruitment Status :
Completed
First Posted : July 18, 2018
Last Update Posted : October 25, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Arthritis, Rheumatoid | Drug: Tripterygium Wilfordii Drug: Methotrexate Drug: Yisaipu | Phase 4 |
This study evaluates the efficacy and safety of YISAIPU plus Tripterygium wilfordii (T2w) for the treatment of RA patients. YISAIPU is a recombinant human tumor necrosis factor receptor fusion protein, and tripterygium wilfordii is a chloroform/methanol extract of Tripterygium wilfordii Hook F.
Objectives:
- To compare the efficacy of YISAIPU plus T2w versus MTX monotherapy for the treatment of signs and symptoms of RA.
- To evaluate the safety of YISAIPU plus T2w in patients with RA for 24 weeks.
Design:
This is a randomized, 24-week, double-blind, parallel group study, and 506 patients with active RA will be randomized in a 1:1:1:1 ratio to one of the following four parallel treatment arms:
- Methotrexate monotherapy
- T2w monotherapy
- YISAIPU plus methotrexate
- YISAIPU plus T2w
Escape:
On week 13, all participants with inadequate response, defined as a <30% improvement of swollen and tender joint counts from baseline, will switch to YISAIPU plus T2w treatment throughout the study.
Endpoints :
- ACR20, ACR50 and ACR70 response rates at 12 and 24 weeks.
- DAS 28 (CRP) and DAS 28 (ESR) at 12 and 24 weeks.
- EULAR response rates at 12 and 24 weeks.
- Health assessment questionnaire (HAQ) at 12 and 24 weeks.
- Patient assessment of arthritis pain at 12 and 24 weeks.
- Patient and physician global assessment of arthritis at 12 and 24 weeks.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 504 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effectiveness and Safety of Tumor Necrosis Factor Receptor Fusion Protein(Yisaipu) Combined With Tripterygium Wilfordii for Active Rheumatoid Arthritis |
Actual Study Start Date : | May 14, 2019 |
Actual Primary Completion Date : | March 20, 2022 |
Actual Study Completion Date : | July 27, 2022 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: MTX
Treated with oral methotrexate and two placebos.
|
Drug: Methotrexate
Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants. |
Placebo Comparator: Tripterygium Wilfordii
Treated with oral Tripterygium Wilfordii and two placebos.
|
Drug: Tripterygium Wilfordii
Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks. |
Active Comparator: Yisaipu + MTX
Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
|
Drug: Methotrexate
Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants. Drug: Yisaipu Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks. |
Experimental: Yisaipu + Tripterygium Wilfordii
Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
|
Drug: Tripterygium Wilfordii
Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks. Drug: Yisaipu Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks. |
- The American College of Rheumatology 50 (ACR50) response at 12 weeks [ Time Frame: week 12 ]The difference of ACR50 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.
- The American College of Rheumatology 20/70 (ACR20/ACR70) response at 12 weeks [ Time Frame: week 12 ]The difference of ACR20 and ACR70 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.
- The American College of Rheumatology 20/50/70 (ACR20/ACR50/ACR70) response at 24 weeks [ Time Frame: week 24 ]The difference of ACR20, ACR50 and ACR70 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 24.
- The Disease Activity Score-28 (DAS28) response at 24 weeks [ Time Frame: week 24 ]
The change in DAS28 score from baseline to week 24 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX).
DAS28 = 0.56*SQRT(TJC28) + 0.28*SQRT(SJC28) + 0.36*ln(CRP + 1) + 0.014*GH + 0.96
- TJC28: The number of tender joints (0-28).
- SJC28: The number of swollen joints (0-28).
- CRP: The C-Reactive Protein level (in mg/l).
- GH: The patient global health assessment (from 0=best to 100=worst).
The 28 joint: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees.
- The European League Against Rheumatism (EULAR) response at 12 weeks [ Time Frame: week 12 ]The difference of proportions of patients meeting EULAR response between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.
- Health Assessment Questionnaire without Didability Index (HAQ-DI) at 12 weeks [ Time Frame: week 12 ]
The change in HAQ-DI score from baseline to week 12 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX).
HAQ-DI is an index measuring the quality of life related to health, which includes 20 questions in terms of three categories:
- from 0 to 1: mild difficulties to moderate disability,
- from 1 to 2: disability moderate to severe,
- from 2 to 3: severe to very severe disability.
The mean score is recorded as the result.
- The Incidence of adverse events during 24-week study [ Time Frame: week 24 ]Incidence of adverse events and sever adverse events (SAE), including hospitalized or Treatment-emergent adverse events, during 24-week study.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18-65 years with informed consent
- Diagnosis of rheumatoid arthritis (according to 2010 ACR/EULAR classification criteria)
- Disease duration > 6 weeks
- Swollen joint (SJC)≥4 and tender joint count(TJC)≥4
- ESR >28 mm/hr or C-reactive protein > 1.5 ULN
- Positive RF or anti-CCP antibody on screening
- Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA
- No evidence of active or latent or inadequately treated Mycobacterium tuberculosis infection
Exclusion Criteria:
- Pregnant, lactating or further fertility requirements
- Previously received any biologic agents.
- Recently (<12 weeks) received methotrexate, leflunomide, salazosulfapyridine, azathioprine, cyclosporine, mycophenolate mofetil or Tripterygium Wilfordii.
- Active or chronic infection, including HIV, HCV, HBV, tuberculosis.
- History of any other rheumatic autoimmune disease
- History of any lymphoproliferative disorder
- Malignancy or history of malignancy.
- Abnormal laboratory tests, including: Hemoglobin <8.5 g/dL, White blood cell count <3.5 x 109/L, Platelet count <100 x 109/L, AST/ALT >1.5 ULN, and serum creatine > 1.5 mg/dL.
- Severe, progressive, or uncontrolled cardiac, pulmonary, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine or neurologic disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03589833
China, Beijing | |
Deptment of Rheumatology, Peking Union Medical College Hospital | |
Beijing, Beijing, China, 100032 |
Principal Investigator: | Xuan Zhang, MD | Peking Union Medical College Hospital |
Responsible Party: | Xuan Zhang, Professor, Peking Union Medical College Hospital |
ClinicalTrials.gov Identifier: | NCT03589833 |
Other Study ID Numbers: |
YISTAR |
First Posted: | July 18, 2018 Key Record Dates |
Last Update Posted: | October 25, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Rheumatoid Arthritis Methotrexate Tripterygium TNF inhibitor |
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Methotrexate Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents |
Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Nucleic Acid Synthesis Inhibitors |